NantKwest (NASDAQ:NK) Stock Rating Upgraded by Zacks Investment Research

NantKwest (NASDAQ:NK) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday, Zacks.com reports.

According to Zacks, “NantKwest, Inc. is a clinical-stage immunotherapy company. The Company’s product candidates include aNK, haNK and taNK for the treatment of cancers, infectious and inflammatory diseases. It is focused on harnessing the power of the innate immune system by using the natural killer cell. NantKwest, Inc. is headquartered in Cardiff-by-the-Sea, California. “

Separately, BidaskClub lowered NantKwest from a “hold” rating to a “sell” rating in a research report on Friday, October 23rd.

NASDAQ:NK opened at $14.78 on Tuesday. NantKwest has a fifty-two week low of $2.52 and a fifty-two week high of $19.37. The stock has a market capitalization of $1.61 billion, a PE ratio of -20.82 and a beta of 2.52. The business’s 50-day simple moving average is $12.33 and its 200-day simple moving average is $10.05.

In other NantKwest news, Director John C. Thomas sold 42,592 shares of the business’s stock in a transaction that occurred on Thursday, December 10th. The stock was sold at an average price of $10.83, for a total transaction of $461,271.36. Following the transaction, the director now owns 207,477 shares of the company’s stock, valued at approximately $2,246,975.91. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Sonja Nelson sold 16,364 shares of the business’s stock in a transaction that occurred on Tuesday, January 12th. The stock was sold at an average price of $15.00, for a total value of $245,460.00. Following the transaction, the chief financial officer now directly owns 31,774 shares in the company, valued at approximately $476,610. The disclosure for this sale can be found here. In the last three months, insiders sold 228,227 shares of company stock worth $3,588,102. 72.08% of the stock is owned by insiders.

Large investors have recently bought and sold shares of the business. Point72 Hong Kong Ltd acquired a new position in shares of NantKwest during the 3rd quarter worth approximately $48,000. Charles Schwab Investment Management Inc. increased its holdings in shares of NantKwest by 23.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 255,225 shares of the biotechnology company’s stock worth $1,770,000 after acquiring an additional 49,222 shares during the last quarter. Principal Financial Group Inc. acquired a new position in shares of NantKwest during the 2nd quarter worth approximately $258,000. Vanguard Group Inc. increased its holdings in shares of NantKwest by 24.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,733,043 shares of the biotechnology company’s stock worth $21,282,000 after acquiring an additional 341,483 shares during the last quarter. Finally, Bank of Montreal Can acquired a new position in shares of NantKwest during the 2nd quarter worth approximately $32,000. 9.22% of the stock is currently owned by hedge funds and other institutional investors.

About NantKwest

NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.

Featured Story: What are municipal bonds?

Get a free copy of the Zacks research report on NantKwest (NK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for NantKwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantKwest and related companies with MarketBeat.com's FREE daily email newsletter.